AVEO Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
CAMBRIDGE, MA, January 30, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Merrill Lynch Nineteenth Annual Global Pharmaceutical, Biotechnology and Medical Device Conference on Wednesday, February 6, 2008 at 1:40 p.m. (ET) at the Grand Hyatt Hotel in New York City.
AVEO is a clinical-stage biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. AVEO’s proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals and Schering-Plough. Through a combination of internal drug discovery and selective in-licensing of targeted therapeutics, AVEO is building a diversified product pipeline and moving toward its vision of becoming a fully integrated biopharmaceutical company. For more information, please visit the company's website at http://aveopharma.com/.